B.Riley FBR Reaffirms Their Buy Rating on Geron (GERN)


In a report released today, Andrew D’silva from B.Riley FBR maintained a Buy rating on Geron (GERN), with a price target of $4.00. The company’s shares closed last Friday at $1.93.

According to TipRanks.com, D’silva is a 4-star analyst with an average return of 6.0% and a 43.4% success rate. D’silva covers the Healthcare sector, focusing on stocks such as Cumberland Pharmaceuticals, EyePoint Pharmaceuticals, and Eton Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Geron with a $3.75 average price target, implying an 81.2% upside from current levels. In a report issued on June 17, Needham also reiterated a Buy rating on the stock with a $3.00 price target.

See today’s analyst top recommended stocks >>

Based on Geron’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $52K and GAAP net loss of $16.36 million. In comparison, last year the company earned revenue of $57K and had a GAAP net loss of $10.06 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts